(TSE: 4503, President and CEO: Naoki Okamura, "Astellas") today announced that the U.S. Food and Drug Administration (FDA) has approved PADCEV (R) (enfortumab vedotin-ejfv), a Nectin-4 directed ...

A new study finds that three existing drugs can force leukemia cells into necroptosis, activating a strong immune response.

Researchers uncovered a powerful weakness in lung cancer by shutting down a protein that helps tumors survive stress. When this protein, FSP1, was blocked, lung tumors in mice shrank dramatically, ...

The importance of minority-interest remeasurement has expanded as joint venture and platform-licensing models become more common in biotech. For investors, such metrics provide an improved lens for ...

The emergence of cancer drug resistance remains one of the most pressing problems in cancer care and there is a critical need ...

The emergence of cancer drug resistance remains one of the most pressing problems in cancer care and there is a critical need ...

The US Patent and Trademark Office (USPTO) has granted a patent to Genprex for the use of its Reqorsa gene therapy in ...

Summit Therapeutics' Ivonescimab targets non-small cell lung cancer through its dual anti-PD-1 plus anti-VEGF mechanism.

The targeted radiotherapies for cancer market is experiencing significant growth, driven by advancements in technology and ...

The Race for the Global Radiotherapy Cancer Market; Actinium Pharmaceuticals' (ATNM) Big Bet To view an enhanced version of ...

At the European Society of Medical Oncology Congress in October 2025 in Berlin, Germany, researchers shared results from the BEACON study, which is the first real-world look at how integrin beta-6 ...

Radiopharm completes enrollment for second cohort of patients in phase 1 dose escalation trial of 177Lu-RAD204 in PD-L1 positive advanced cancers: Sydney Saturday, November 15, 20 ...